Item no. |
HY-16381A-50mg |
Manufacturer |
MedChem Express
|
CASRN |
396091-76-2 |
Amount |
50 mg |
Category |
|
Type |
Molecules |
Specific against |
other |
Purity |
99.82 |
Formula |
C60H70N10O11 |
Citations |
[1]Lewis I, et, al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem. 2003 Jun 5;46(12):2334-44.<br>[2]Quinn TJ, et, al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery. 2012 Dec;152(6):1068-77.<br>[3]Imhof AK, et, al. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis. Arthritis Rheum. 2011 Aug;63(8):2352-62.<br>[4]Imhof AK, et, al. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis. Arthritis Rheum. 2011 Aug;63(8):2352-62.<br>[5]Schmid HA, et, al. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008 May 14;286(1-2):69-74. |
Smiles |
NCCCC[C@@H](C(N[C@H]1CC2=CC=C(C=C2)OCC3=CC=CC=C3)=O)NC([C@H](NC([C@H](C4=CC=CC=C4)NC([C@H]5N(C([C@H](CC6=CC=CC=C6)NC1=O)=O)C[C@H](OC(NCCN)=O)C5)=O)=O)CC7=CNC8=C7C=CC=C8)=O.CC(O)=O |
ECLASS 10.1 |
32169090 |
ECLASS 11.0 |
32169090 |
UNSPSC |
12000000 |
Alias |
SOM230 (acetate) |
Available |
|
Product Description |
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity[1][2][3]. |
StorageTemperature |
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen) |
Shipping |
Blue Ice |
Manufacturers Applications |
Metabolism-sugar/lipid metabolism |
MolecularWeight |
1107.26 |
Clinical_Information |
Launched |
Manufacturers Research_Area |
Cancer; Endocrinology |
Solubility |
DMSO : 100 mg/mL (ultrasonic)|H2O : 1 mg/mL (ultrasonic; warming; heat to 60°C) |
Manufacturers Target |
Somatostatin Receptor |
Pathway |
GPCR/G Protein; Neuronal Signaling |
Manufacturers Product type |
Peptides |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.